Opus Genetics (IRD) Liabilities and Shareholders Equity (2010 - 2026)

Opus Genetics (IRD) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $66.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 38.66% year-over-year to $66.8 million; the TTM figure through Mar 2026 stood at $191.8 million (up 12.67% YoY), while the FY2025 annual figure was $50.2 million, up 36.3% from the prior year.
• Liabilities and Shareholders Equity climbed to $66.8 million in Q1 2026 per IRD's latest filing, from $50.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $66.8 million in Q1 2026 and bottomed at $14.6 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $41.9 million across 5 years, with a median of $44.8 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity sank 37.22% — and 2023, when it surged 271.99%.
• Opus Genetics' Liabilities and Shareholders Equity stood at $49.0 million in 2022, then grew by 10.12% to $53.9 million in 2023, then sank by 31.67% to $36.9 million in 2024, then surged by 36.3% to $50.2 million in 2025, then jumped by 32.93% to $66.8 million in 2026.
• Business Quant data shows IRD's Liabilities and Shareholders Equity at $66.8 million in Q1 2026, $50.2 million in Q4 2025, and $36.1 million in Q3 2025.